TOKEN2049
8.9.2022 10:46:43 CEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, announced the DJ line-up of AFTER 2049, the official closing event of this year’s September edition. Headlined by Istanbul-based DJ and producer Carlita, electronic icon DJ Tennis, and Moojo, Mo-Shi and Leon (Calamar Crew), AFTER 2049 will be taking place on Friday, 30 September as it takes over the rooftop of the city's most iconic building, Marina Bay Sands.
Occupying both the iconic observation deck that offers unparalleled, uninterrupted views of the Singapore skyline, and CÉ LA VI, one of Singapore’s most iconic nightlife institutions, AFTER 2049 will be hosted in tandem with the first practice round of the Formula 1 Singapore Grand Prix 2022. The exclusive event will feature exhilarating views of the night race at what’s set to be the Singapore Grand Prix race weekend’s largest party.
Raphael Strauch, Founder of TOKEN2049 said: “AFTER 2049 is our way of thanking our community, partners and speakers who’ve supported us from day one. We’re thrilled to be bringing some of the biggest names in electronic music, while showcasing some of the rising stars in the region. Coming on the back of what’s going to be Asia’s largest crypto event with over 5,000 attendees, AFTER 2049 is set to raise the bar for nightlife events in Singapore and the broader Asia Pacific region.”
A limited number of tickets for AFTER 2049 will be sold via Resident Advisor from 13 September onwards.
TOKEN2049 Singapore marks the conference’s Singapore debut which runs from 28 to 29 September ahead of the Singapore Grand Prix race weekend. Sponsors of AFTER 2049 include Asia’s one-stop gateway to Web 3.0 and one of the region’s leading providers of non-custodial staking services RockX; core blockchain infrastructure company Parity Technologies; leading blockchain and digital currency-focused venture capital firm Cypher Capital; one-stop, cross-chain aggregator for decentralised finance and metaverse products XY Finance; Asia-based full-stack proprietary venture capital firm Newman Capital; and Singapore-based crypto unicorn and digital assets financial services platform Matrixport.
Attendees will be able to hear from some of the industry’s leading entrepreneurs and thought leaders on all aspects of the broader crypto and Web3 arena. As part of Asia Crypto Week, TOKEN2049 attendees can expect to attend a full line-up of side events, conferences, networking events, workshops, and parties taking place throughout the week.
Additional sponsors for AFTER 2049 include leading South Korean game company Wemade; world’s largest cryptocurrency derivatives copy trade platform Bitget; the EOS Network Foundation which is building a coordinated future for the EOS Network through decentralization and community; digital asset exchange AAX; global online identity verification platform Trulioo; cryptocurrency and derivatives exchange OKX; decentralised and open-source protocol Syscoin; global digital assets exchange Zipmex; and collaborative Web3 credential infrastructure Galxe.
To purchase tickets for AFTER 2049, please visit: https://ra.co/events/1578263.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/.
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom